Barclays Issues Positive Forecast for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its target price raised by Barclays from $6.50 to $7.50 in a research note issued to investors on Wednesday, MarketBeat reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s target price indicates a potential downside of 3.85% from the company’s current price.

CERT has been the subject of a number of other reports. KeyCorp decreased their target price on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. Robert W. Baird reduced their price objective on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Morgan Stanley decreased their price objective on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Craig Hallum decreased their price objective on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a report on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.95.

Certara Trading Down 4.6%

CERT opened at $7.80 on Wednesday. Certara has a 1-year low of $4.45 and a 1-year high of $13.88. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.21 billion, a P/E ratio of -78.00 and a beta of 1.44. The company has a fifty day moving average price of $6.41 and a two-hundred day moving average price of $6.56.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. Certara’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.07 EPS. Analysts predict that Certara will post 0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Certara

Institutional investors and hedge funds have recently made changes to their positions in the business. Central Pacific Bank Trust Division boosted its stake in Certara by 8.7% during the 2nd quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock valued at $127,000 after purchasing an additional 1,558 shares during the last quarter. Kopion Asset Management LLC increased its holdings in Certara by 44.2% during the 2nd quarter. Kopion Asset Management LLC now owns 1,858,539 shares of the company’s stock worth $12,173,000 after purchasing an additional 570,087 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Certara by 28.1% in the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after purchasing an additional 2,871 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Certara by 292.2% in the first quarter. Bank of America Corp DE now owns 2,042,946 shares of the company’s stock worth $11,645,000 after purchasing an additional 1,522,034 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Certara by 12.1% in the first quarter. The Manufacturers Life Insurance Company now owns 23,289 shares of the company’s stock valued at $133,000 after purchasing an additional 2,513 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.